基于患者人群和丙型肝炎病毒基因型的索磷布韦/维帕他韦/伏西瑞韦获益-风险评估:美国食品药品监督管理局的评价
2017年7月18日,美国食品药品监督管理局(FDA)批准索磷布韦/维帕他韦/伏西瑞韦(SOF/VEL/VOX)固定剂量复方制剂用于特定慢性丙型肝炎病毒(HCV)感染成人患者。批准基于两项3期临床试验中可接受的安全性特征和高持续病毒学应答率(SVR12)。本文阐述FDA在评估VOX对SOF/VEL的贡献以及不同基因型和患者人群差异时的考量,并解释为何NS5A抑制剂经治患者获得广谱适应症(基因型1-6)而NS5A抑制剂初治患者适应症仅限于基因型1a和3。
要点
- SOF/VEL/VOX于2017年7月18日获FDA批准用于无肝硬化或代偿期肝硬化(Child-Pugh A)的特定HCV成人患者。
- POLARIS-1中96%的SOF/VEL/VOX治疗患者达到SVR12,POLARIS-4中98%达到SVR12。
- FDA对NS5A抑制剂经治患者给予基因型1-6广谱适应症,对NS5A抑制剂初治患者仅限基因型1a和3。
核心结论
- FDA基于可接受的安全性特征和两项3期试验的高SVR12率批准SOF/VEL/VOX用于特定HCV患者。
- NS5A抑制剂经治患者的适应症为HCV基因型1-6,而NS5A抑制剂初治患者的适应症仅限于基因型1a和3。
研究设计与样本
- 美国食品药品监督管理局(FDA)对SOF/VEL/VOX固定剂量复方制剂用于慢性HCV感染成人患者的获益-风险评估。
- 评估基于两项3期临床试验(POLARIS-1和POLARIS-4)中既往接受直接抗病毒药物(DAA)方案治疗受试者的数据。
主要发现
- POLARIS-1中,96%的SOF/VEL/VOX治疗受试者达到SVR12。
- POLARIS-4中,98%的SOF/VEL/VOX治疗受试者达到SVR12。
关键数值与推荐
- SOF/VEL/VOX获批用于无肝硬化或代偿期肝硬化(Child-Pugh A)的基因型1、2、3、4、5或6感染且既往接受过含NS5A抑制剂方案治疗的患者。
- SOF/VEL/VOX获批用于无肝硬化或代偿期肝硬化(Child-Pugh A)的基因型1a或3感染且既往接受过含索磷布韦但不含NS5A抑制剂方案治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On July 18, 2017, the U.S. Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing a nonstructural protein 5A (NS5A) inhibitor; and • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Approval was based on an acceptable safety profile and high sustained virological response rates 12 weeks after the end of treatment (SVR12) in two phase 3 clinical trials in subjects previously treated with a direct-acting antiviral (DAA) regimen. In POLARIS-1, 96% of SOF/VEL/VOX-treated subjects achieved SVR12. In POLARIS-4, 98% of SOF/VEL/VOX-treated subjects achieved SVR12. A key and challenging question in evaluating the data was determining the contribution of VOX to SOF/VEL and how this differed depending on the genotype and patient population. In this article, we provide our perspective on the issues considered in making these determinations, especially regarding the POLARIS-4 data in subjects who have previously been treated with a chronic HCV regimen containing sofosbuvir without an NS5A inhibitor. Conclusion: We seek to provide context as to why a broad indication was given for NS5A inhibitor-experienced patients (HCV genotypes 1-6) while the indication for NS5A inhibitor- naïve patients was limited to HCV genotypes 1a and 3 only. (Hepatology 2018;67:482-491).
引用
- Struble K, Chan-Tack K, Qi K, et al. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Hepatology. 2018. PMID: 29059462. doi:10.1002/hep.29601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。